Current treatment for cutaneous leishmaniasis: a review
- PMID: 19300044
- DOI: 10.1097/MJT.0b013e3181822e90
Current treatment for cutaneous leishmaniasis: a review
Abstract
Cutaneous leishmaniasis is the most common form of leishmaniasis. It is a skin infection caused by a single-celled parasite that is transmitted by sand fly bites. There are about 20 species of Leishmania that may cause cutaneous leishmaniasis. Some Leishmania species are closely linked to humans and are therefore found in cities (Leishmania tropica), whereas some are more traditionally associated with animal species and are therefore considered zoonoses (Leishmania major). The evidence for optimal treatment of cutaneous leishmaniasis is patchy. Although the cutaneous form of the disease is often self-limiting, it does result in significant scarring and can spread to more invasive, mucocutaneous disease. Therefore, treatment may be considered to prevent these complications. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use, and adverse effects.
Similar articles
-
Evidence for leishmania (viannia) parasites in the skin and blood of patients before and after treatment.J Infect Dis. 2006 Aug 15;194(4):503-11. doi: 10.1086/505583. Epub 2006 Jul 10. J Infect Dis. 2006. PMID: 16845635
-
Treatment strategies for mucocutaneous leishmaniasis.J Glob Infect Dis. 2010 May;2(2):147-50. doi: 10.4103/0974-777X.62879. J Glob Infect Dis. 2010. PMID: 20606970 Free PMC article.
-
Treatment of cutaneous leishmaniasis among travellers.J Antimicrob Chemother. 2004 Feb;53(2):158-66. doi: 10.1093/jac/dkh058. Epub 2004 Jan 16. J Antimicrob Chemother. 2004. PMID: 14729756 Review.
-
Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis.Int J Dermatol. 2009 Jul;48(7):758-62. doi: 10.1111/j.1365-4632.2009.04072.x. Int J Dermatol. 2009. PMID: 19570087 Clinical Trial.
-
Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis.Expert Rev Anti Infect Ther. 2010 Apr;8(4):419-33. doi: 10.1586/eri.10.19. Expert Rev Anti Infect Ther. 2010. PMID: 20377337 Review.
Cited by
-
Dipeptidyl peptidase 3, a novel protease from Leishmania braziliensis.PLoS One. 2018 Jan 5;13(1):e0190618. doi: 10.1371/journal.pone.0190618. eCollection 2018. PLoS One. 2018. PMID: 29304092 Free PMC article.
-
Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.PLoS One. 2015 May 26;10(5):e0122569. doi: 10.1371/journal.pone.0122569. eCollection 2015. PLoS One. 2015. PMID: 26009885 Free PMC article.
-
HAS 1: A natural product from soil-isolated Streptomyces species with potent activity against cutaneous leishmaniasis caused by Leishmania tropica.Front Pharmacol. 2022 Oct 10;13:1023114. doi: 10.3389/fphar.2022.1023114. eCollection 2022. Front Pharmacol. 2022. PMID: 36299890 Free PMC article.
-
Antileishmanial Activity of Ziziphus spina-christi Leaves Extract and Its Possible Cellular Mechanisms.Microorganisms. 2021 Oct 7;9(10):2113. doi: 10.3390/microorganisms9102113. Microorganisms. 2021. PMID: 34683434 Free PMC article.
-
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.Am J Trop Med Hyg. 2010 Aug;83(2):351-6. doi: 10.4269/ajtmh.2010.10-0060. Am J Trop Med Hyg. 2010. PMID: 20682881 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources